Creatine Beyond Muscle
Creatine has a reputation problem. Ask most people what it does and they will tell you it helps you lift heavier weights. That answer is not wrong, but it misses the bigger picture: creatine is one of the most abundant small molecules in the human body, and its job is to keep energy flowing wherever cells work hardest. Muscle happens to be the most famous customer. It is not the only one.
Over the past decade, a research group at the University of Colorado has been asking a surprising question: does creatine matter for the gut? More specifically, could a shortage of creatine inside intestinal cells help explain inflammatory bowel disease, and could creatine supplementation help treat it? Dr. Caroline Hall, a pediatric gastroenterologist and researcher at the University of Colorado and Children’s Hospital Colorado, laid out the case in a recorded research talk on creatine supplementation for patients with inflammatory bowel diseases. Her presentation, together with the peer reviewed studies behind it, forms the backbone of this article.
A note on honesty before we start. The story you are about to read is genuinely exciting, but the human evidence for creatine and IBD currently consists of cell experiments, animal studies, one published case report, and one small clinical trial that has not yet reported results. That places creatine firmly in the early evidence category for this use. Nobody, including the researchers themselves, is claiming creatine treats IBD today. What they are claiming is that the biology is compelling enough to test properly, and that is exactly what is happening.
Inflammatory Bowel Disease Basics
Inflammatory bowel disease, or IBD, is a group of chronic inflammatory conditions of the digestive tract that cycle through flares and quieter stretches, often for life. Hall notes in her talk that it affects roughly 1 to 2 percent of American adults. National data lands in that neighborhood: the Centers for Disease Control and Prevention estimates that between 2.4 and 3.1 million adults in the United States live with IBD, which works out to around 1 percent of the adult population, and prevalence is rising. Historically the disease has been most common in the United States, Canada, Europe, and Australia, but as Hall points out, case numbers are climbing across the rest of the world too.
IBD can appear at any age, but the peak years for diagnosis fall between roughly 15 and 30. That early onset is one reason a pediatric gastroenterologist like Hall sees so much of it, and it also means many patients face decades of living with the condition.
The IBD umbrella covers two main diseases. Crohn’s disease can strike anywhere along the digestive tract, from the mouth to the anus, typically in scattered patches with healthy tissue in between, and the inflammation can burrow through the full thickness of the bowel wall. Ulcerative colitis, by contrast, stays in the large intestine, spreads in a continuous stretch starting from the rectum, and remains confined to the innermost surface layer of the colon lining. Under the endoscope and the microscope, both diseases share a common signature that matters for this story: a damaged, distorted, inflamed intestinal lining where there should be a smooth protective surface.
The Treatment Gap
Modern IBD treatment has improved enormously, and Hall is careful to acknowledge that current medications help many patients. But she is equally frank about their limits. Most advanced IBD therapies work by suppressing the immune system throughout the body. That approach carries real tradeoffs, including an increased risk of infections and, with some drug classes, malignancy. Many of these medications also require injections or intravenous infusions, which is a meaningful burden for people managing a lifelong disease.
Then there is the effectiveness problem. Hall states that even the best available therapies achieve remission in only about 30 to 40 percent of patients, leaving a majority with disease that is not fully controlled. The published literature backs her up. Researchers writing in The Lancet Gastroenterology and Hepatology have described a therapeutic ceiling in ulcerative colitis, with remission rates for new drugs in induction trials sitting at a modest 20 to 30 percent, and a 2026 analysis in the same journal notes that remission rates across IBD appear to plateau at 30 to 50 percent after a year of treatment despite an expanding menu of drugs.
To be clear, none of this means people with IBD should question their prescribed therapy, which for any individual patient may be working well and preventing serious complications. It means the field urgently needs additional options: treatments with fewer side effects, easier administration, and better results. Hall’s argument is that an inexpensive, orally taken, widely studied nutritional compound deserves a look, especially as an addition to existing care rather than a replacement for it.
The Gut Barrier and Its Energy Bill
Why would an energy molecule matter in an inflammatory disease? The answer starts with the intestinal barrier.
The lining of your intestine is a single layer of epithelial cells performing one of the most demanding balancing acts in the body. On one side sits the gut contents: partially digested food and trillions of bacteria. On the other side waits your immune system. The epithelial cells form a living wall between the two, and the seals between neighboring cells, called tight junctions, are what keep bacterial fragments and food particles from leaking through. Hall explains that when this barrier is disrupted, luminal contents come into contact with immune cells, which respond with inflammation. Sustained barrier failure and the resulting chronic inflammation sit at the heart of how researchers understand IBD, alongside genetics, immune dysregulation, environmental exposures, and an imbalanced gut microbiome.
Here is the crucial detail: maintaining that barrier is astonishingly expensive in energy terms. Tight junction proteins are not installed once and left alone. They are continuously shuttled to and from the junctions, held in position by a scaffold of actin filaments that is itself constantly being built and rebuilt. All of that trafficking and cytoskeletal remodeling burns through adenosine triphosphate, or ATP, the universal energy currency of cells. Work from the Colorado group has estimated that the actin cytoskeleton alone consumes nearly a fifth of the total energy available within the intestinal epithelium.
The idea that IBD might partly be an energy problem is older than you might think. Hall points to a paper published more than 40 years ago, in 1980, in which the surgeon and researcher William Roediger examined colon cells from patients with ulcerative colitis and found they had a diminished ability to burn butyrate, the fatty acid that normally serves as the colon’s main fuel, leaning instead on glucose. He proposed that ulcerative colitis might be, at its core, a disease of energy deficiency in the colon lining. The tools to properly test that idea did not exist in 1980. They do now.
The Creatine System in the Gut
Creatine is a small compound the body both makes and eats. Your kidneys and liver produce roughly a gram per day using two enzymes, AGAT and GAMT, and the rest arrives through diet, with meat and fish as the main food sources. An average adult carries in the range of 120 to 140 grams of creatine, most of it stored in muscle. Cells take creatine up through a dedicated doorway, the creatine transporter, a protein known as SLC6A8 or CrT.
Once inside a cell, creatine does something elegant. Creatine kinase enzymes attach a phosphate group to it, creating phosphocreatine, which acts as a rapid rechargeable battery. When ATP is consumed at some busy location in the cell, phosphocreatine instantly regenerates it on the spot, and the system shuttles energy from the mitochondria, where it is produced, to the sites where it is spent. This is why tissues with high and fluctuating energy demands, such as muscle, heart, and brain, are loaded with creatine machinery. Intestinal epithelial cells, it turns out, carry the same equipment, with the creatine transporter sitting on the cell surface that faces the gut contents, positioned to capture dietary creatine directly.
The gut adds a twist: oxygen is scarce there by design. The intestinal surface sits next to an essentially oxygen free interior, and research from Sean Colgan’s group, a key collaborator of Hall’s, has shown that the healthy gut lining lives in a state of what researchers call physiologic hypoxia, with oxygen pressure at the surface measured below 10 millimeters of mercury, far lower than in most other tissues. Hall shows in her talk that inflammation makes this dramatically worse: in a mouse colitis model, staining for hypoxia reveals low oxygen spreading deeper and more intensely through inflamed tissue.
Cells respond to low oxygen by activating hypoxia inducible factor, or HIF, a master switch that reprograms metabolism. And this is where creatine enters the IBD story. In 2013, Louise Glover, Colgan, and colleagues published a study in the Proceedings of the National Academy of Sciences showing that HIF directly and coordinately controls the creatine machinery, including the creatine kinases and the creatine transporter. They found that a creatine kinase concentrates at the junctions between intestinal cells, that blocking the creatine kinase pathway prevents proper junction assembly and destroys barrier integrity, and that creatine kinase expression is altered in tissue from IBD patients. In other words, the gut appears to use the creatine system as a built in mechanism for powering its barrier, especially under the low oxygen conditions of inflammation.
The creatine connection may not stop at the barrier. The review that Wallimann, Hall, Colgan, and Glover published in the journal Nutrients in 2021 catalogs evidence that immune cells themselves run on the creatine system: macrophages import creatine through the same transporter, and creatine levels shape how those cells polarize and respond to inflammatory signals, while creatine uptake also regulates the activity of certain T cells. The same review compiles findings that creatine protects a variety of cell types against low oxygen, oxidative stress, and programmed cell death, and can lower circulating inflammatory markers in endurance athletes. Since IBD involves both a failing barrier and a misfiring immune response, a molecule that touches both sides of that equation is an intriguing candidate, though these broader effects remain far less established in the gut specifically.
That discovery set up the driving hypothesis of Hall’s work: if the intestinal barrier runs on creatine, then a broken creatine supply line could contribute to the barrier failure seen in IBD, and restoring creatine might help repair it.
Creatine Loss and the Leaky Barrier
Hall’s team put that hypothesis through an unusually thorough series of tests, published in the journal Gastroenterology in 2020. They started with the most direct question: do IBD patients actually have less creatine transporter in their gut lining? Examining colon biopsies from 27 patients with ulcerative colitis, 30 with Crohn’s disease, and 30 people without IBD, they found that transporter expression was significantly reduced in ulcerative colitis. In Crohn’s disease the picture was more nuanced: patients with inactive disease showed the same significant reduction, but the difference washed out in actively inflamed Crohn’s tissue, which Hall suggests may reflect the flood of immune cells crowding into inflamed samples rather than a true recovery. Glover’s earlier work had found a matching pattern for the creatine kinases CKB, CKM, and CKMT1, which are reduced in both Crohn’s disease and ulcerative colitis.
Location told its own story. When the researchers stained intestinal cells for the creatine transporter alongside ZO1, a marker of tight junctions, the transporter sat at the same level in the cell, directly adjacent to the junctions, and healthy human tissue showed the same arrangement. The energy doorway is installed exactly where the energy is needed.
Next came the functional experiments. Using siRNA, a technique for dialing down a specific gene, the team created intestinal cell lines with a partial and a near complete loss of the creatine transporter. The full knockdown cells held about half the normal amount of creatine. When grown on membranes that allow barrier strength to be measured as electrical resistance, the results lined up in a neat staircase: normal cells built a strong barrier, partial knockdowns built a mediocre one, and full knockdowns built the weakest of all. A second test confirmed it, showing that a fluorescently tagged sugar molecule leaked across the transporter deficient cell layers far more readily. The team then repeated the experiment in colonoids, miniature gut linings grown from the cells of mice genetically lacking the creatine transporter, and again the barrier failed to form properly.
Why does the barrier fail? The team traced it to the tight junctions themselves. Cells lacking the transporter made less claudin 1, a junction protein that tightens the barrier, and more claudin 2, a pore forming protein that makes it leakier. Remarkably, the human biopsies mirrored this exactly: patient by patient, more creatine transporter tracked with more claudin 1 and less claudin 2, while ZO1 showed no relationship. The junction proteins were also in the wrong place. In healthy cells they trace a crisp chicken wire pattern along cell borders; in the knockout cells they smeared into blobs trapped inside the cell. Hall’s group linked this to the actin scaffold, showing that transporter deficient cells largely fail to polymerize the actin needed to anchor junctions in position, which fits the idea that this construction work simply costs more energy than a creatine starved cell can pay.
The deficits went beyond the barrier. In a scratch wound assay, where a uniform gap is cut into a sheet of cells and healing is tracked over time, transporter knockout cells repaired the wound significantly more slowly. Metabolic profiling added a final piece: when pushed with metabolic stressors, normal cells ramped up both glycolysis and mitochondrial respiration, but the knockout cells could raise only glycolysis, revealing a lost reserve of mitochondrial capacity, consistent with creatine’s role in ferrying energy from mitochondria to the rest of the cell. The cells did try to compensate, nudging up their own creatine synthesis enzymes, with a significant rise in AGAT in the knockout colonoids, but it was not enough to restore normal function.
And the effect ran in both directions. When the team engineered cells to overexpress the creatine transporter, the cells built a stronger barrier faster, with a trend toward better wound closure. More creatine capacity, better barrier. Less creatine capacity, leakier barrier and slower healing. As correlations go, this one comes with an unusually complete mechanistic chain.
Evidence From Animal Studies
Cell experiments are tidy, but colitis happens in living organisms, so the next question was whether dietary creatine could protect an inflamed gut in an animal. Hall describes an experiment using TNBS, a chemical that reliably triggers acute colitis in mice. Mice on normal chow that received TNBS lost a significant amount of body weight, and some died. Mice whose chow was supplemented with 2 percent creatine held their weight almost as if they had never been injured, and none died. Under the microscope, the difference was just as stark: the normal chow mice showed severe destruction of the intestinal lining, while the creatine fed mice showed substantial protection, quantified as lower scores for both immune cell infiltration and tissue injury. This echoes the group’s earlier published work, which reported that oral creatine supplementation markedly reduced disease severity and inflammation in both TNBS and DSS mouse colitis models.
Independent evidence points the same way. Hall’s collaborator Theo Wallimann and colleagues describe, in their 2021 review in the journal Nutrients, a massive genetic screen by the laboratory of Nobel laureate Bruce Beutler, in which tens of thousands of randomly mutated mice were tested for susceptibility to colitis. One of the susceptibility mutations that emerged sat in AGAT, one of the two enzymes for making creatine. Mice carrying it suffered more intestinal cell death and worse colitis when challenged, and supplementing those mice with creatine significantly improved their disease. In 2023, the Colorado group added another piece in the journal Mucosal Immunology, showing that mice engineered to lack creatine kinases develop significantly more severe experimental colitis.
Taken together, the animal work forms a consistent triangle: damage the creatine system, whether the transporter, the synthesis enzymes, or the kinases, and colitis gets worse; supply extra creatine, and colitis gets better. The essential caveat is that these are mice with chemically induced colitis, which is a model of human IBD, not the disease itself. Plenty of interventions that cured mouse colitis have failed in people. Animal data can justify a human trial; it cannot substitute for one.
A Remarkable Case Report
There is exactly one published human case, and it is a striking one. Reported by Abhik Roy and David Lee in the ACG Case Reports Journal in 2016, and highlighted by Hall in her talk, it involves a 33 year old man with a two year history of abdominal pain and rectal bleeding. A colonoscopy in early 2015 revealed mild Crohn’s disease of the terminal ileum, scoring 4 on a standard endoscopic severity scale, and it emerged that he had been taking a creatine supplement at the time of diagnosis. His care team started mesalamine, a common IBD medication, and he stopped the creatine.
Over the following four months his pain grew steadily worse. A repeat colonoscopy showed the disease had progressed despite the mesalamine, with larger ulcers covering more of the intestinal surface and the endoscopic score rising to 7. Before escalating to stronger drugs, the patient asked to try resuming his old creatine supplement, about a gram of creatine hydrochloride daily, because he felt his symptoms had been better on it. Months later, a third colonoscopy showed marked improvement: only small scattered ulcers and an endoscopic score of 3, better than at diagnosis.
It is worth being blunt about what this does and does not show. One patient is an anecdote, not a trial. Crohn’s disease naturally waxes and wanes, there was no placebo, and nothing was blinded, so the improvement could have had nothing to do with creatine. But the timing, with disease worsening off creatine and improving back on it, tracked the supplement closely enough that the treating physicians considered it worth publishing, and it fits the mechanism uncovered in the lab. Cases like this generate hypotheses. Trials test them.
The Ulcerative Colitis Trial
That trial exists. Hall’s group, working with adult gastroenterologist Mark Gerich at the University of Colorado, designed a randomized, placebo controlled, blinded pilot study, registered on ClinicalTrials.gov as NCT02463305 under the title Therapeutic Modulation of the Intestinal Creatine Kinase System in Inflammatory Bowel Disease, with approval from an institutional review board.
The design targets adults aged 18 to 70 with mild to moderately active ulcerative colitis, confirmed by a Mayo Score of 3 to 10 with visible inflammation on endoscopy, and with disease extending beyond the rectum. Participants take creatine monohydrate or a matching placebo daily for eight weeks. On dosing, the records vary slightly with protocol version: Hall describes 14 grams per day in her talk, the published rationale paper specifies 7 grams twice daily, and the trial registry describes 21 grams per day in three divided doses. Every version is a supervised research dose several times higher than the 3 to 5 grams typical of everyday supplementation. Importantly, this is not a monotherapy study. Patients already taking mild IBD medications, specifically mesalamine or thiopurines, continue them throughout, so creatine is being tested as an addition to standard care.
The primary outcome is the one that matters most in modern IBD research: endoscopic and histologic improvement, judged by comparing colonoscopies and biopsies taken before and after the eight weeks. Secondary outcomes cast a wide net, including symptom severity and quality of life questionnaires, inflammatory markers in blood and stool, direct measures of intestinal barrier permeability, creatine and creatine kinase levels, and changes in the gut microbiome. Participants randomized to placebo are offered open label creatine afterward.
Expectations should be sized to the study. With roughly a dozen participants, this pilot is built to establish feasibility, tolerability, and a preliminary signal of efficacy, not to deliver a definitive verdict. Hall frames it exactly that way, describing it as the foundation for what could come next: longer treatment trials, a creatine monotherapy trial, which the Nutrients authors propose at 3 to 5 grams twice daily for three to six months, and a trial combining creatine with metformin. The metformin idea is the most speculative of the three. Metformin activates AMPK, a cellular energy sensor involved in assembling the junctions between intestinal cells, and people with type 2 diabetes taking metformin show a reduced risk of IBD in retrospective data, so the two compounds might support gut energetics in complementary ways. For now that is a hypothesis on paper. As of this writing, the pilot trial remains listed as an active early phase study and no results have been published, so the honest summary is that the definitive human evidence is still ahead of us.
Practical Takeaways
Where does all of this leave someone standing in a supplement aisle? A fair reading of the evidence looks like this. The mechanistic case that intestinal cells use creatine to power their barrier is strong and comes from multiple independent laboratories. The animal evidence that creatine protects against experimental colitis is consistent. The human evidence consists of one published case report and one small trial without published results. By any honest standard, creatine for IBD is an early stage research story, which is exactly the evidence rating this article carries. Promising biology is not the same thing as a proven treatment, and the history of medicine is full of promising biology that did not survive contact with a randomized trial.
If you have IBD, the practical guidance is clear. Do not stop or replace any prescribed therapy with creatine; notice that even the researchers testing creatine keep their trial participants on standard medications. Bring the idea to your gastroenterologist, who knows your disease, your medications, and your labs. One useful detail for that conversation: creatine supplementation can modestly raise blood levels of creatinine, a routine marker doctors use to assess kidney function, without indicating actual kidney harm, so your care team should know you are taking it before interpreting your bloodwork.
For generally healthy people, creatine itself has an unusually deep safety record. The International Society of Sports Nutrition’s position stand, which reviewed hundreds of studies, concluded that creatine monohydrate is safe and well tolerated in healthy individuals at doses up to 30 grams per day for as long as five years, with 3 to 5 grams per day being the standard maintenance amount. Digestive complaints are uncommon at those doses, though some people report bloating or loose stools with large single servings, which usually resolves by splitting the dose and taking it with food. It is also worth remembering that meat and fish are the main dietary sources of creatine, so people eating little or no animal protein take in very little from food and rely almost entirely on what their bodies synthesize.
The bigger lesson of Hall’s work may be the reframe it offers. We tend to think of the gut barrier as a wall and of IBD as an immune system gone rogue. This research suggests the wall is better understood as a construction site that never closes, staffed by cells with an enormous energy bill, and that at least part of the disease may come down to those cells being unable to pay it. Whether topping up the creatine supply can genuinely change the course of ulcerative colitis or Crohn’s disease is a question the Colorado trial, and hopefully larger studies after it, will answer. A 2026 narrative review in the Journal of Nutritional Biochemistry shows a growing research community now taking that question seriously. Until the human data arrive, the right posture is the one Hall herself models: genuine excitement, held to the standard of evidence.